Global Psychiatry Partnering Deal Trends, Players and Financials Directory 2019

DUBLIN, March 28, 2019 /PRNewswire/ — The “Global Psychiatry Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

Global Psychiatry Partnering 2014 to 2019 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2014. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report Scope

Global Psychiatry Partnering 2014 to 2019 includes:

  • Trends in Psychiatry dealmaking in the biopharma industry since 2014
  • Analysis of Psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Psychiatry deal contract documents
  • Comprehensive access to over 3500 Psychiatry deal records
  • The leading Psychiatry deals by value since 2014
  • Most active Psychiatry dealmakers since 2014

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In Global Psychiatry Partnering 2014 to 2019, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Psychiatry dealmaking

2.1. Introduction

2.2. Psychiatry partnering over the years

2.3. Psychiatry partnering by deal type

2.4. Psychiatry partnering by industry sector

2.5. Psychiatry partnering by stage of development

2.6. Psychiatry partnering by technology type

2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering

3.1. Introduction

3.2. Disclosed financials terms for Psychiatry partnering

3.3. Psychiatry partnering headline values

3.4. Psychiatry deal upfront payments

3.5. Psychiatry deal milestone payments

3.6. Psychiatry royalty rates

Chapter 4 – Leading Psychiatry deals and dealmakers

4.1. Introduction

4.2. Most active in Psychiatry partnering

4.3. List of most active dealmakers in Psychiatry

4.4. Top Psychiatry deals by value

Chapter 5 – Psychiatry contract document directory

5.1. Introduction

5.2. Psychiatry partnering deals where contract document available

Chapter 6 – Psychiatry dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Psychiatry therapeutic target

Appendices

Appendix 1 – Directory of Psychiatry deals by company A-Z 2014 to 2019

Appendix 2 – Directory of Psychiatry deals by deal type 2014 to 2019

Appendix 3 – Directory of Psychiatry deals by stage of development 2014 to 2019

Appendix 4 – Directory of Psychiatry deals by technology type 2014 to 2019

For more information about this report visit https://www.researchandmarkets.com/research/btzk7s/global_psychiatry?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

WHAT TO READ NEXT...
kimano